Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
about
Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID miceDisabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinasesA potential role for colony-stimulating factor 1 in the genesis of the early endometriotic lesion.Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemiaAgeing is a risk factor in imatinib mesylate cardiotoxicityLoss of p53 impedes the antileukemic response to BCR-ABL inhibitionRare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate.The biology of chronic myelogenous leukemia:mouse models and cell adhesion.The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitorsRetroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatmentEffect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.Src kinase signaling in leukaemiaEffects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.Smooth muscle hyperplasia due to loss of smooth muscle α-actin is driven by activation of focal adhesion kinase, altered p53 localization and increased levels of platelet-derived growth factor receptor-β.Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.Evolution of therapies for chronic myelogenous leukemia.An overview of chronic myeloid leukemia and its animal models.In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension.Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis.Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice.Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.Imatinib activates pathological hypertrophy by altering myocyte calcium regulation.Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.Murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders.STAT5 signaling is required for the efficient induction and maintenance of CML in mice.A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.Occurrence of de novo ABL kinase domain mutations in primary bone marrow cells after BCR-ABL gene transfer and Imatinib mesylate selection.
P2860
Q24309051-27B1646C-4DFC-4950-B961-2F18D18BF410Q28258417-322B0109-C69A-4C3D-BB17-CDF56F92B87BQ33615748-1BD3B9D0-8C67-4CD1-B3F6-D9AC0D69F8B1Q33747277-F1B47D91-4C28-471D-85CE-AD46B5874604Q34546468-8A71D702-6E2A-4E83-BDD3-ECCE16A1891EQ34548719-BF5F2B4A-3DB6-49FE-B95B-12C58BBE70BAQ34585293-AA3C7E5A-1063-4125-8E57-B5C96EF7A72EQ35012761-14B57F26-EE05-4CCC-8575-FC5D8AD84D57Q35022536-A22E2EAB-B6D9-4876-A836-6E05C8FA48ADQ35022540-A5688088-B5A7-47E3-998D-7572B1CE38CDQ35119075-647B255B-8D37-4555-9DA3-DD154EA60ED4Q35128883-93ED7384-2ADE-4497-87A0-D026FA3438E3Q35166848-3D4B91E2-6283-4ED5-91FE-B7ED7FC5EC45Q35459748-02A18326-C407-4C0C-A908-243A9F088BF3Q35663526-8F558E61-0D7E-4CA4-8091-E447CF42BFFAQ35752831-42A0849C-8057-407D-9871-9AA0399642D5Q35847727-EF497C01-BB5C-4BEE-A107-552DC81194FCQ35900937-807D6E86-1F80-4F86-B435-3ACE8654BB82Q35986641-F4A6F7E4-0B19-4F57-8340-DE1C5FE90733Q36116937-149E5069-EB10-4023-8B5F-4E3BAB8EF7A9Q36286872-F7E79FFC-FDF8-49BB-9841-4C17E281EB4BQ36334327-6F2F8784-5271-4183-A644-DDAC41985752Q36854122-3B1FFB12-F11D-4338-8214-66A0FC3F084EQ36975163-72635CF2-F1DC-4451-A082-A52F8299A877Q37390598-38011D97-A8FB-4401-953B-9C9276960D0DQ37966915-08E52AA4-2C3F-4D93-8902-46193084E699Q38637889-7997F7BC-D16D-46DF-89B5-4617F52BE55EQ38913950-E02F045C-77CC-4120-B315-1F70B32C35F0Q39331272-ED46E02C-4F37-40B7-B9A7-15CA062B2E69Q40230301-62E88833-A912-49A0-A686-3EDC9B442D52Q40571427-0C03CA5F-69D3-4C5F-9544-E526DB165C0DQ41673629-9F9306EE-8DC7-4BA7-8FAF-507D92D8D7FEQ42143116-540CDC16-87A6-43B6-AADD-1E32065E1EF4Q42381521-A22D29C7-59C0-4ADB-9AD7-EAD7509E0B38Q42721777-B043AD4F-B466-4BCF-BD99-4A8666F1F983Q42741768-95226E10-0EA3-4C67-9FB4-CD1D1531E060Q44645852-CDF4041D-348A-4CE7-9FE6-5164B3574280Q44851706-2D5B875C-1C71-4B58-AED9-A539C25850A7Q45061059-B96289AA-765B-4987-9DC7-FDEC4E63365FQ46497567-D75B6C30-C8AA-45E4-A591-02835CBC68EF
P2860
Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Establishment of a murine mode ...... osine kinase inhibitor STI571.
@en
Establishment of a murine mode ...... osine kinase inhibitor STI571.
@nl
type
label
Establishment of a murine mode ...... osine kinase inhibitor STI571.
@en
Establishment of a murine mode ...... osine kinase inhibitor STI571.
@nl
prefLabel
Establishment of a murine mode ...... osine kinase inhibitor STI571.
@en
Establishment of a murine mode ...... osine kinase inhibitor STI571.
@nl
P356
P1433
P1476
Establishment of a murine mode ...... osine kinase inhibitor STI571.
@en
P2093
Ilaria RL Jr
P304
P356
10.1182/BLOOD.V98.9.2808
P407
P577
2001-11-01T00:00:00Z